
    
      This is a randomized, double-blind, placebo-controlled, multicenter study to assess the
      safety and efficacy of Anamorelin in patients with non-small cell lung cancer-cachexia
      (NSCLC-C). The primary efficacy analysis will include the treatment difference in the change
      in lean body mass and physical function.
    
  